[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"French Cardiology Society\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":344},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,69,98,122,147,173,199,221,243,271,298,319],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100606511","multivalve--a-prospective-multicentre-study-of-multiple-and-mixed-valvular-heart-disease-100606511",false,"NCT07176507","MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Heart Disease","MULTIVALVE","Inclusion Criteria:\n\n* Age ≥18 years\n* The patient has been informed of the study and has not refused to participate.\n* An echocardiographic diagnosis of MMVD is defined as having at least two moderate to severe valvulopathies, as assessed by a cardiologist using transthoracic echocardiography (TTE), on one or more valves. This is in line with the recommendations of the ESC, the ASE, and expert opinion.\n\nExclusion Criteria:\n\n* History of valve surgery or percutaneous valve intervention involving the valve in question.\n* A history of infective endocarditis, whether treated surgically or not, confirmed according to the modified Duke criteria.\n* Acute infective endocarditis at the time of evaluation for inclusion, confirmed according to the modified Duke criteria.\n* Complex congenital heart disease.\n* Patients who are already included in the European EACVI-MMVD study.\n* Pregnant women\n* Patients not affiliated to social security\n* Patients who are minors\n* Patients under guardianship, curatorship or judicial supervision\n* Patients who refuse to participate in this register.","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","5 Years","OBSERVATIONAL","Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres.\n\nIn order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease.\n\nThe multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.",[25],"Valvular Heart Disease",[27,28,29],"valvular heart disease","Multiple and mixed valvular heart disease","multiple valve disease","RECRUITING","2026-06-11",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":34},"2025-10-30",{"date":38,"type":20},"2032-10",{"name":40,"class":41},"French Cardiology Society","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100280084","management-and-clinical-outcomes-of-patients-with-severe-mitral-valve-disease-not-suitable-for-surgery-100280084","NCT02925819","Management and Clinical Outcomes of Patients With Severe Mitral Valve Disease Not Suitable for Surgery","Management And Clinical Outcomes Of Patients With Severe Mitral Disease Not Suitable For Surgery: A Prospective, Multicentric, Observational Study","MITRAGISTER","* Aged over 18 years\n* Presenting with severe mitral valve stenosis or regurgitation regardless of etiology (primary mitral regurgitation, secondary mitral regurgitation, deterioration of mitral valve repair or bioprosthesis, mitral annular calcification)\n* Symptomatic (NYHA functional class II-IV) despite optimized medical therapy\n* Judged not eligible for surgical treatment according to a specialized multidisciplinary meeting called \"heart team\" comprising at least one cardiothoracic surgeon, one interventional cardiologist, one echocardiographer, one clinical cardiologist and one anaesthesiologist.\n* Having received information about the study and not expressing opposition to the use of their data\n* Patient not included in a clinical trial\n\nExclusion Criteria:\n\n* Asymptomatic patients\n* Absence of severe mitral regurgitation or stenosis\n* Patient judged eligible for surgical treatment according to a specialized multidisciplinary meeting called \"heart team\" comprising at least one cardiothoracic surgeon, one interventional cardiologist, one echocardiographer, one clinical cardiologist and one anaesthesiologist.\n* Pregnant or breastfeeding women\n* Having not received information about the study or having expressed opposition to the use of their data",{"count":52,"type":20},500,"2 Years","The objective of this study is to collect in a prospective registry all cases of French patients undergoing an assessment for percutaneous treatment of mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement. In these patients, valvular surgery should be considered contra-indicated or at prohibitive risk. This registry will evaluate the morbidity and mortality up to 24 months for those patients with severe mitral valve disease who are not included in a clinical trial. The association of demographic, clinical, laboratory, echocardiographic variables and treatment options with morbidity and mortality will be evaluated by univariate and multivariate analyses.",[56],"Mitral Valve Disease",[58,59,60,61],"Mitral regurgitation","Mitral stenosis","Mitral valve repair deterioration","Bioprosthesis degeneration",{"date":33,"type":34},{"date":64,"type":34},"2016-10",{"date":66,"type":20},"2026-12",{"name":40,"class":41},3,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100628536","diaphragmatic-evaluation-by-fluoroscopy-to-identify-phrenic-nerve-dysfunction-related-to-electroporation-100628536","NCT07462910","Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation","Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation Prospective Multicentre Study on the Evaluation of the Incidence of Diaphragmatic Paralysis After Pulsed Field Ablation Procedures to Treat Atrial Fibrillation","DEFINE-PFA","Inclusion Criteria:\n\n* Men and women aged 18 years or older at the time of signing the consent (age≥ 18).\n* Diagnosis of paroxysmal or persistent atrial fibrillation, documented in any type of means: ECG, Holter, invasive monitoring (memories of an implantable device) or not (connected objects).\n* Indication for ablation decided as part of routine care, according to the recommendations of learned societies.\n* First, ablation procedure (including pulmonary vein isolation) planned with the use of a commercially available Pulsed Field Ablation catheter.\n* Possibility of performing a fluoroscopic diaphragmatic evaluation before and after the operation (before discharge from the hospital).\n* Free, informed and signed consent by the patient before any data collection\n\nExclusion Criteria:\n\n* Known history of diaphragmatic paralysis (right or bilateral) or pre-existing clinical suspicion.\n* History of atrial fibrillation ablation.\n* History of neuromuscular disease.\n* History of major thoracic surgery or chronic pulmonary pathology that may impair diaphragmatic kinetics.\n* Evidence of diaphragmatic paralysis on the pre-procedure fluoroscopy loop, defined as:\n\n  * Cranio-caudal excursion amplitude ≤35 mm on both hemidiaphragms, Or\n  * An asymmetry in contraction amplitude ≥15% between the two sides.\n* Inability to perform a post-procedure follow-up fluoroscopy (logistical limitation, patient refusal, contraindication to irradiation).\n* Pregnancy or breastfeeding in progress.\n* Concurrent participation in another interventional study that may interfere with the objectives of this research.\n* Major impairment in cognitive function or inability to understand the objectives of the study or sign a valid consent.\n* Individuals deprived of liberty by judicial or administrative decision.\n* Adults subject to a legal protection measure (guardianship, curatorship, or judicial protection\u002Fsafeguard of justice).\n* Individuals unable to provide informed consent.",{"count":78,"type":20},250,"INTERVENTIONAL",[81],"NA","Pulsed Field Ablation (PFA) represents a recent advance in the treatment of atrial fibrillation (AF), with a safety profile potentially superior to traditional thermal techniques, such as radiofrequency or cryoablation. Its mechanism of action allows tissue selectivity which in theory limits damage to extracardiac structures. However, several cases of right diaphragmatic paralysis have been reported in the literature after PFA, particularly during applications on the right pulmonary veins, near the right phrenic nerve. The available data are from studies without specific diaphragmatic monitoring. The diagnosis of diaphragmatic paralysis is most often based on chest X-ray, a static examination of limited sensitivity, especially for the detection of incomplete paralysis. To date, no prospective multicentre study has evaluated the incidence of diaphragmatic paralysis after PFA with systematic dynamic imaging, such as fluoroscopy, considered the gold standard for the diagnosis of unilateral paralysis.",[84],"Atrial Fibrillation",[86,87,88],"Pulsed Field Ablation","Fluoroscopy","Diaphragmatic monitoring","2026-06-08",{"date":91,"type":34},"2026-06-10",{"date":93,"type":34},"2026-06-02",{"date":95,"type":20},"2027-05-31",{"name":40,"class":41},9,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":107,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},"100536243","a-safety-and-effectiveness-monitoring-in-france-for-aveir-vr-lp-and-aveir-ar-lp-france-leadless-100536243","NCT06262295","A Safety and Effectiveness Monitoring in France for AVEIR VR LP and AVEIR AR LP (France LEADLESS)","France LEADLESS, A Safety and Effectiveness Monitoring in France for AVEIR VR LP and AVEIR AR LP","FranceLEADLESS","Inclusion Criteria:\n\n* The patient has been or will be implanted with device AVEIR VR LP and\u002For device AVEIR AR LP\n* Patient over 18 years old\n* Patient informed of the nature of the study, agrees to participate in the study\n\nExclusion Criteria:\n\n* Patient under 18 years of age\n* Patient refusing to participate in the study",{"count":19,"type":20},"36 Months","Although the idea of a leadless pacemaker was first proposed in the 1970s to eliminate the probes, pockets and connectors required by conventional cardiac procedures and the associated complications, the first devices were not developed until the late 2010s. Leadless pacemakers can also improve patient comfort by replacing surgery with a percutaneous procedure, eliminating the mass and scar visible at the implantation site of a conventional pacemaker, and eliminating the need for activity restrictions to prevent dislodgement after implantation of a conventional lead.\n\nThis french Registry \"France LEADLESS\" is a national registry designed to confirm the safety and efficacy of the AVEIR VR LP System in a patient population indicated for the implantation of a VVI(R) pacemaker in France and the AVEIR AR LP System in a population of patients indicated for the implantation of an AAI(R) pacemaker or both systems used in conjunction in a population of patients indicated for the implantation of a DDD(R) pacemaker. This registry will also make it possible to collect the characteristics and indications of patients under normal conditions of use.",[110],"Pacemaker",[112,110],"Leadless stimulator","2026-03-06",{"date":115,"type":34},"2026-03-09",{"date":117,"type":34},"2024-02-14",{"date":119,"type":20},"2029-09",{"name":40,"class":41},1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":132,"studyType":22,"phases":4,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":121},"100551851","post-marketing-clinical-study-of-the-lambre-system-for-left-auricle-closure-100551851","NCT06465459","Post-marketing Clinical Study of the LAMBRE System for Left Auricle Closure","ESCALLE : Post-marketing Clinical Study of the LambrE System for Left Auricle Closure","ESCALLE","Inclusion Criteria:\n\n* Patient requiring a left atrial exclusion procedure according to the recommendations by the CNEDiMTS and HAS using the LAMBRE device\n* Age ≥18 years\n* Patient has been informed of the nature of the study and agrees to participate\n\nExclusion Criteria:\n\n* Minor patient\n* Patient refusing to participate in the study or unable to give informed consent (patient under guardianship, curatorship or safeguard of justice)",{"count":131,"type":20},220,"12 Months","Atrial fibrillation (AF) is responsible for 15-20% of ischaemic strokes. These events are often caused by thrombus formation in the left atrium. Thromboembolic risk in AF is primarily prevented by oral anticoagulation. However, this drug-based approach has a number of limitations, the most important of which are compliance problems and, above all, the risk of haemorrhagic complications, some of which are potentially serious. Left atrial appendage closure is a therapeutic alternative for the prevention of cardioembolic risk in cases where anticoagulation is clearly contraindicated.\n\nThe CNEDiMTS opinion of 12 March 2019 defines that the LAMBRE, LIFETCH prosthesis, a device for transcatheter closure of the left atrial appendage, is authorised for the prevention of thromboembolic events in patients with non-valvular atrial fibrillation at high risk of thromboembolic events with a CHA2DS2-VASc score ≥ 4 and a formal and permanent contraindication to anticoagulants (validated by a multidisciplinary committee).\n\nLAMBRE prosthesis in France are subject to a review of the results by the CNEDIMTS committee. Among the criteria analysed regarding the efficacy and safety of the device implantation, the result regarding the migration rate of the LAMBRE device will be one of the criteria enabling the Commission to decide on the appropriateness of the renewal of the registration.",[84],[136,137,138],"non-valvular atrial fibrillation","atrial fibrillation","LAMBRE system","2026-02-27",{"date":141,"type":34},"2026-03-02",{"date":143,"type":34},"2024-06-10",{"date":145,"type":20},"2027-12",{"name":40,"class":41},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":42},"100626222","assessment-of-the-association-between-sleep-disorders-detected-by-a-simplified-questionnaire-and-cardiovascular-diseases-100626222","NCT07432828","Assessment of the Association Between Sleep Disorders Detected by a Simplified Questionnaire and Cardiovascular Diseases","Assessment of the Association Between Sleep Disorders Detected by a Simplified Questionnaire and Cardiovascular Diseases: a Prospective Study in Cardiology Consultations","CARDIOSOM","Inclusion Criteria - Patient :\n\n* Adult patients (≥18 years old) consulting in cardiology.\n* Ability to complete the questionnaire.\n* No objection\n\nInclusion Criteria - Cardiologist:\n\nCardiologists who participated in CARDIOSOM and who conduct cardiology consultations that include a systematic or non-systematic assessment of their patients' sleep quality (duration, regularity, insomnia, sleepiness, suspected obstructive sleep apnea (OSA)) and whether or not suspected sleep disorders in patients are treated.\n\nExclusion Criteria - Patient :\n\n* Active treatment for a severe sleep disorder (severe sleep apnea under CPAP (Continuous Positive Airway Pressure) or orthotic device, narcolepsy, chronic insomnia being treated)\n* Refusal to participate\n\nExclusion Criteria - Cardiologist :\n\nNot applicable",{"count":156,"type":20},1500,"The goal of this observational study is to validate a simplified questionnaire, adapted for routine clinical use, to quickly detect sleep disorders in patient during a cardiology consultation.\n\nTwo questionnaires were developed for this project. The first is patient-oriented: a prospective, multicentre, national observational registry based on a patient questionnaire designed to quickly detect sleep disorders during a cardiology consultation.\n\nThe second is aimed at treating cardiologists: this is a simple impact survey designed to assess changes in the practices of cardiologists who participated in CARDIOSOM.",[159,160],"Sleep Disorder (Disorder)","Cardio Vascular Disease",[162,163,164],"sleep disorders","risk of cardiovascular conditions","simplified questionnaire","2026-02-19",{"date":167,"type":34},"2026-02-25",{"date":169,"type":34},"2026-01-15",{"date":171,"type":20},"2027-01",{"name":40,"class":41},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":180,"sex":181,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":79,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":121},"100621610","womens-heart-impact-of-ultra-endurance-and-hormonal-profile-on-cardiac-and-systemic-inflammatory-parameters-in-female-runners-100621610","NCT07372859","Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners","COEUR","Inclusion Criteria:\n\n* Must have a Global Positioning System watch during the race;\n* Must participate in one of the following races:\n\n  * \"Ecotrail de Paris Ile France©\" (=a trail running race in the Paris region, it is not possible to translate; it is a registered trademark) 80 kilometers;\n  * Or \"la 6000D©\" 69 kilometers;\n* Must comply with the race regulations:\n\n  * Medical certificate stating no contraindications to competitive running, dated less than 12 months prior to the race;\n  * Or a valid sports license on the day of the race.\n* Must agree to participate in the study, sign the consent form, and allow the sponsor to use their data for the purposes of this study.\n\nExclusion Criteria:\n\n* Refusal or linguistic or mental incapacity to sign the informed consent form;\n* Person under guardianship (conservatorship, curators, or legal protection) or deprived of liberty;\n* Person not affiliated with a social security scheme;\n* Pregnant woman;\n* Person participating in a drug study;\n* Women with a medical history (chronic lung disease, heart disease, pharmacologically treated hypertension) or with a known significant chronic inflammatory disease at the time of the enrollment visit;\n* Person who has already participated in this study in a previous race.",true,"FEMALE",{"count":183,"type":20},120,[81],"The goal of this clinical trial is to describe the cardiac and systemic inflammatory adaptations specific to women practicing ultra-endurance sports.\n\nThe objectives are to:\n\n* Improve the understanding of cardiac and systemic inflammatory adaptations specific to women participating in ultra-endurance sports.\n* Assess the relationship between observed cardiac and systemic inflammatory alterations and the relative levels of estrogen, testosterone, and progesterone.\n* Describe the vascular adaptations specific to women participating in ultra-endurance sports.\n* Examine the influence of defense mechanisms on the emotional dynamics observed during and after an ultra-endurance race.",[187],"Healthy Volunteer",[189],"ultra endurance","NOT_YET_RECRUITING","2026-01-23",{"date":193,"type":34},"2026-01-28",{"date":195,"type":20},"2026-03-22",{"date":197,"type":20},"2026-09-30",{"name":40,"class":41},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":181,"minAge":17,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":121},"100606881","wamif-prospective-study-in-young-women-presenting-acute-myocardial-infarction-cohort-follow-up-100606881","NCT07181317","WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction: Cohort Follow up","WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction in France: Clinical, Morphological and Biological Descriptive Analysis: Cohort Follow up","WAMIF-suivi","All patients who participated in the WAMIF study (research registration number with the French Ministry of Health : 2015-A01263-46 \u002F Protocol registration with Clinical Trials NCT03073447) and wish to continue follow-up in the study.","60 Years",{"count":209,"type":20},314,"The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their short-term (in-hospital) and medium-term (12-month) prognosis. Extending the follow-up beyond 12 months for this first study would provide fundamental data for understanding and improving the care of these patients.",[212],"Myocardial Infarction, Acute","2026-01-09",{"date":215,"type":34},"2026-01-12",{"date":217,"type":34},"2025-11-25",{"date":219,"type":20},"2029-09-30",{"name":40,"class":41},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":79,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":121},"100607797","microflow3d---non-invasive-mapping-of-coronary-arteries-and-the-cerebral-vascular-network-using-3d-ultrasound-localization-microscopy-in-patients-with-atherosclerosis-prior-to-carotid-endarterectomy-surgery-100607797","NCT07193225","Microflow3D - Non-invasive Mapping of Coronary Arteries and the Cerebral Vascular Network Using 3D Ultrasound Localization Microscopy in Patients With Atherosclerosis Prior to Carotid Endarterectomy Surgery","Non-invasive Mapping of Coronary Arteries and the Cerebral Vascular Network Using 3D Ultrasound Localization Microscopy in Patients With Atherosclerosis Prior to Carotid Endarterectomy Surgery - Microflow3D","Microflow3D","Inclusion Criteria:\n\n* Patients with asymptomatic carotid stenosis, without recent stroke, and scheduled for carotid endarterectomy within the next 30 days.\n* Age ≥ 18 years.\n* Beneficiary of a social security system or equivalent coverage.\n* Signed informed consent.\n* Patients already enrolled in another biomedical research study may also participate in this study.\n\nExclusion Criteria:\n\n* Contraindication to the use of the ultrasound contrast agent SonoVue®: known hypersensitivity to the active substance or to any of the following excipients: Macrogol 4000; Distearoylphosphatidylcholine; Sodium dipalmitoylphosphatidylglycerol; Palmitic acid.\n* Allergy to ultrasound gel.\n* Refusal or inability (linguistic or psychological) to sign the informed consent form.\n* Subject to legal protection measures, such as guardianship (in accordance with Article L1122-2 of the French Public Health Code).\n* Pregnant or breastfeeding women cannot participate in this study.",{"count":230,"type":20},37,[81],"There is a need to simplify the assessment of coronary and cerebral vascular networks in patients selected for carotid endarterectomy in order to prevent potential complications during and after surgery. A non-invasive, non-ionizing 3 dimension mapping of these networks would provide a remarkable benefit for patients.",[234],"Carotid Atherosclerosis","2025-09-18",{"date":237,"type":34},"2025-09-25",{"date":239,"type":20},"2025-11-01",{"date":241,"type":20},"2027-11-30",{"name":40,"class":41},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":79,"phases":253,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},"100580118","atrioventricular-node-ablation-and-conduction-system-pacing-in-patients-with-well-controlled-permanent-atrial-fibrillation-af-heart-failure-and-preserved-ejection-fraction-heart-rate-regularization-versus-medical-rate-control-100580118","NCT06833138","Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate Control","Atrioventricular (AV) Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization vs. Medical Rate Control","HF-RELIEF","Inclusion Criteria:\n\n* Permanent atrial fibrilation \\> 6 months\n* Preserved Left Ventricular Ejection Fraction ≥ 50%\n* ≥ 1 heart failure hospitalization in the previous year\n* NYHA (New York Heart Association) score ≥ 2\n* Presence of at least one of the following criteria related to diastolic dysfunction:\n\n  * E\u002Fe' ratio \\> 9\n  * Left Ventricular mass \\> 95 g\u002Fm2 (female) or \\> 115 g\u002Fm2 (male) with h\u002FR ratio \\> 0.42\n  * NT pro BNP (B-type Natriuretic Peptide) \\> 365 pg\u002FmL or BNP (B-type Natriuretic Peptide) \\> 105 pg\u002FmL\n* Narrow QRS ≤ 120 ms\n* Average heart rate ≤ 110\u002Fmin on 24 hours Holter monitoring\n* Age over 18-year-old\n* Capacity to understand the nature of the study, legal ability and willingness to give informed consent\n* Patient covered by a social insurance\n* Effective contraception and a negative pregnancy test in women of a childbearing age\n\nExclusion Criteria:\n\n* Patient eligible for atrial fibrilation catheter ablation\n* Life expectancy \\\u003C 12 months\n* Severe chronic kidney disease (estimated Glomerular Filtration Rate ≤ 20 ml\u002F1,73 m2)\n* Severe respiratory disease (severe chronic obstructive pulmonary disease with Gold ≥ 3 and\u002For chronic oxygen therapy)\n* Class III obesity (Body Mass Index ≥ 40)\n* Confirmed or suspected infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others)\n* Obstructive hypertrophic cardiomyopathy\n* Previous implanted devices (Pacemaker \u002F Implantable Cardioverter-Defibrillator \u002F Cardiac Resynchronization Therapy)\n* Other indication for pacemaker implantation\n* Indication for implantable cardioverter-defibrillator\n* Ambulatory ≤ 50% of time\n* Pregnant women\n* Breast-feeding women",{"count":252,"type":20},266,[81],"The goal of this clinical trial is to assess the clinical efficacy of physiological pacing combined with atrioventricular node ablation, in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and well controlled permanent atrial fibrillation.The main question it aims to answer is that heart rate regularization added to physiological pacing - preventing the deleterious effect of right ventricular apical pacing - would reduce mortality and heart failure hospitalizations.\n\nResearchers will compare physiological pacing combined with atrioventricular node ablation (intervention arm) versus optimal pharmacological therapy (control arm) to see if physiological pacing combined with atrioventricular node ablation reduce time to the composite of all-cause mortality or hospitalization due to heart failure or intravenous diuretics (time frame 24 months).\n\nParticipants will :\n\n* Be randomized in intervention arm or control arm.\n* Visit the clinic 3 months, 12 months and 24 months after the randomization for checkups and tests.",[256,257],"Heart Failure With Preserved Ejection Fraction","Atrial Fibrillation, Persistent",[259,260,261],"Heart failure","Cardiac Resynchronization Therapy","Conduction System Pacing","2025-09-17",{"date":264,"type":34},"2025-09-22",{"date":266,"type":34},"2025-09-10",{"date":268,"type":20},"2029-12-31",{"name":40,"class":41},15,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":79,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":121},"100354486","noninvasive-elastography-evaluation-of-myocardial-stiffness-in-elderly-patients-with-isolated-diastolic-heart-failure-new-diagnostic-tool-100354486","NCT03895541","Noninvasive Elastography Evaluation of Myocardial Stiffness in Elderly Patients With Isolated Diastolic Heart Failure: New Diagnostic Tool?","ELASTOCARDIO2","Global Inclusion Criteria:\n\n* Hospitalization in cardiology services for acute pulmonary edema during heart failure\n* Natriuretic peptide type B ≥35 pg\u002Fml\n* Echocardiographic structural alteration\n\nSpecific Inclusion criteria\n\n* Group \"preserved LVEF\": Left ventricular Ejection Fraction ≥50%\n* Group \"moderate alteration of LVEF\": Left ventricular Ejection Fraction between 40% and 49%\n* Group \"Systolic heart failure\": Left ventricular Ejection Fraction\\\u003C 40%\n\nGlobal Exclusion Criteria:\n\n* Other associated lung pathology\n* Other heart disease\n* Contraindication to MRI or echocardiography gel\n* Pregnancy\n* Poor echogenicity,","80 Years",{"count":280,"type":20},90,[81],"The new approach propose in this protocol is based on ultrafast ultrasound and remote palpation of tissue by ultrasonic radiation pressure. Ultrafast ultrasound of biological tissues is based on an innovative ultrasound imaging approach that can image very fast soft tissue events at a rate of several thousands of frames per second and provide quantitative mapping of the elasticity of the tissues. This current project aims is to focus on myocardial rigidity in diastole to better assess the function of the heart failure.",[284],"Cardiovascular Diseases in Old Age",[286,287,288,289],"heart failure","myocardial rigidity","new diagnosis","ultrasound imaging","2025-03-10",{"date":292,"type":34},"2025-03-11",{"date":294,"type":34},"2020-01-24",{"date":296,"type":20},"2025-12-31",{"name":40,"class":41},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":305,"targetDuration":307,"studyType":22,"phases":4,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":121},"100192205","registry-of-aortic-valve-bioprostheses-established-by-catheter-100192205","NCT01777828","Registry of Aortic Valve Bioprostheses Established by Catheter","FRANCE-TAVI","Inclusion Criteria: Patients who have undergone transarterial or transapical aortic valve bioprosthesis implantation\n\nExclusion Criteria: Patient has not given consent",{"count":306,"type":20},5000,"10 Years","The aim of this registry is to evaluate the overall survival up to 10 years of patients with aortic valve bioprostheses implanted via the transarterial or transapical route. Data from the register is enhanced by matching it with continuous data in the SNDS.\n\nMandated by the French health authorities, this registry must be maintained as part of the management of any patient undergoing transarterial or transapical aortic valve bioprosthesis implantation.\n\nParticipation in the registry is offered to all subjects eligible for bioprosthesis implantation.",[310],"Transcatheter Aortic Valve Implantation","2025-02-12",{"date":313,"type":34},"2025-02-14",{"date":315,"type":34},"2013-02",{"date":317,"type":20},"2034-02",{"name":40,"class":41},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":121},"100139870","french-hypertrophic-cardiomyopathy-observatory-100139870","NCT01091480","French Hypertrophic Cardiomyopathy Observatory","REMY","Inclusion Criteria:\n\n* Age ≥ 15 years old\n* Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic\n\nExclusion Criteria:\n\n* Expressed refusal to participate in the study\n* Significant aortic stenosis (\\\u003C1 cm ²)","15 Years",{"count":328,"type":20},600,"Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use.\n\nThe purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)",[331],"Hypertrophic Cardiomyopathy",[333,334,335],"Hypertrophic cardiomyopathy","Observatory","LVH","2022-09-20",{"date":338,"type":34},"2022-09-21",{"date":340,"type":34},"2010-01",{"date":342,"type":20},"2028-12",{"name":40,"class":41},""]